On March 29, the paper, “Carotid artery plaque intervention with Tongxingluo capsule(CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study”, which was led by Zhang Yun, an academician of Qilu Hospital of Shandong University, was announced at the annual meeting of Chinese interventional heart disease, and also was published in the international scientific journal "Nature", "Science Report"

This study is the first clinical evidence-based study of Chinese herbal medicine intervention in carotid plaque, which confirmed that Chinese medicine Tongxinluo can safely and effectively delay the progress of carotid plaque area and vascular remodeling, using evidence and internationally recognized evaluation to reconfirm the effectiveness and safety of TCM.

Zhang Yun further pointed out that the study concluded that the application of Tongxinluo treatment can delay the progression of carotid mean intima-media thickness, plaque area and vascular remodeling index, reduce cardiovascular events, and have good safety.

Leading by Zhang Yun, Tongxinluo Capsules conducted by 35 domestic hospitals intervened in carotid plaque evidence-based medicine research, which screened 1212 cases of carotid atherosclerotic plaques among 18 provinces in China. On the basis of routine treatment, Tongxinluo Capsule was added to observe the changes of the intima-media thickness, plaque area and vascular remodeling index of bilateral carotid arteries after 2 years of treatment.

The study concluded that Tongxinluo Capsule can effectively reduce the plaque volume and reduce the risk of plaque rupture, thus reducing the risk of cerebral infarction. Therefore, comprehensive evaluation of Tongxinluo can prevent myocardial infarction and cerebral infarction recurrence in patients with stable cardiovascular and cerebrovascular diseases, and achieve secondary prevention.

At present, the related research of Tongxinluo Capsule, which is national essential drugs, has won one second prize of national technical invention and two second prizes of national scientific and technological progress. In 2017, the oral Chinese patent medicine for cardiovascular diseases, Tongxinluo Capsule accounted for 6.92%, which became the basic medicine for treating cardiovascular and cerebrovascular diseases. It has been registered and sold in Korea, Vietnam, Russia, Canada, Singapore, Cambodia and other countries, and was approved by the Vietnamese Ministry of Health to enter the Vietnam National Health Insurance Directory.

Source: http://www.satcm.gov.cn/

Time: 2019.04.01